Alternate site testing for HbA1c using the Primus CLC330 GHb analyzer

Current methods for measuring HbA1c in diabetic patients often rely on centralized laboratory testing, which may delay results and limit flexibility in outpatient settings. While point-of-care devices like the DCA-2000 allow for faster results, they may lack the precision of traditional high-pressure liquid chromatography (HPLC) methods. However, the potential for alternate site testing (AST) using HPLC remains unclear. Prior research has shown that HPLC is a reliable method for HbA1c measurement, but its suitability for AST has not been fully established. This uncertainty drives the need to evaluate HPLC systems like the Primus for AST compatibility. No prior work has resolved whether HPLC can maintain accuracy and precision in AST conditions. Existing studies have focused on device-specific limitations, but broader methodological comparisons remain limited. The challenge lies in balancing rapid processing with high accuracy in a clinical setting. This gap motivates a detailed evaluation of the Primus HPLC for AST use.

The study aimed to assess whether the Primus HPLC is suitable for alternate site testing (AST) of HbA1c in a hospital diabetes outpatient clinic. The goal was to determine if this method could meet AST requirements while maintaining accuracy and precision. Researchers focused on comparing the Primus HPLC with other established methods like the Pierce affinity minicolumn and the DCA-2000. The motivation was to identify a reliable alternative to traditional centralized testing for HbA1c. The study also aimed to evaluate the impact of uremia on HbA1c measurements using the Primus HPLC. Researchers wanted to ensure the method was not prone to interference from carbamylated hemoglobin. This investigation sought to address the limitations of existing AST devices by exploring a more robust HPLC system. The ultimate aim was to provide a faster and more accurate HPLC-based AST solution for diabetes management.

The study evaluated the Primus HPLC for alternate site testing (AST) of HbA1c in a hospital diabetes outpatient clinic. HbA1c measurements were taken from diabetic patients, including those with uremia. The Primus HPLC was compared to other methods such as the Pierce affinity minicolumn and the DCA-2000 using a 6-minute assay cartridge. Researchers measured imprecision at different HbA1c levels to assess reliability. They also evaluated interference from carbamylated hemoglobin, a known issue with ion-exchange HPLC methods. A limited number of patients were tested with the DCA-2000 to compare results. Method comparison studies were conducted to assess bias and proportional error between the Primus and other techniques. The study also examined the effect of time intervals between sequential injections on HbA1c readings.

The Primus HPLC demonstrated low imprecision with values of 2.3%, 1.6%, and 1.0% for HbA1c levels of 4.7%, 7.3%, and 11.1%, respectively. The method was not prone to interference from carbamylated hemoglobin, unlike the ion-exchange Variant HPLC. Method comparison studies showed a bias of -0.4% and proportional error of 1.2% between the Primus HPLC and Pierce affinity minicolumn (n = 32). The bias and proportional error between the Primus and DCA-2000 were 0.7% and -2.5%, respectively. The Primus HPLC produced falsely elevated HbA1c concentrations when the time between injections exceeded 28 minutes. The study found that the Primus outperformed the DCA-2000 in AST settings by maintaining accuracy and allowing batch processing. The method's precision met the requirements for AST in outpatient clinics. These findings suggest the Primus HPLC is a viable option for AST in diabetes management.

The authors concluded that the Primus HPLC is well-suited for alternate site testing (AST) of HbA1c in a hospital diabetes outpatient clinic. The method demonstrated low imprecision and was not affected by carbamylated hemoglobin interference. The study found that the Primus HPLC provided results comparable to other methods like the Pierce affinity minicolumn and the DCA-2000. The authors propose that the Primus offers advantages over existing AST devices by allowing rapid automated batch processing. The study suggests that the Primus can be used effectively in AST conditions without compromising accuracy. The authors note that the Primus HPLC may be a better option for AST than the DCA-2000 due to its precision and reliability. The findings indicate that the Primus HPLC is a suitable alternative for AST in diabetes management. The authors suggest that this method could improve the efficiency of HbA1c testing in outpatient settings.